ID   MM253c1-1T
AC   CVCL_UM67
DR   cancercelllines; CVCL_UM67
DR   Wikidata; Q95990208
RX   PubMed=3756862;
RX   PubMed=7060019;
CC   Selected for resistance to: ChEBI; CHEBI_72568; MTIC (5-(3-methyl-1-triazeno)imidazole-4-carboxamide).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_UM66 ! MM253c1
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=3756862;
RA   Maynard K., Parsons P.G.;
RT   "Cross-sensitivity of methylating agents, hydroxyurea, and
RT   methotrexate in human tumor cells of the Mer- phenotype.";
RL   Cancer Res. 46:5009-5013(1986).
//
RX   PubMed=7060019;
RA   Parsons P.G., Smellie S.G., Morrison L.E., Hayward I.P.;
RT   "Properties of human melanoma cells resistant to
RT   5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other
RT   methylating agents.";
RL   Cancer Res. 42:1454-1461(1982).
//